Mobocertinib (TAK-788) has received FDA Priority Review for the treatment of adult patients with epidermal growth factor receptor Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer, as detected by an FDA-approved test, who have received prior platinum-based chemotherapy.
In 1996, Lei Zheng, a graduate of Peking Union Medical College, enrolled in the doctorate program at what was then known as the Cancer Therapy & Research Center in San Antonio.
